UBS Group’s China SXT Pharmaceuticals SXTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $108K | Buy |
62,599
+57,329
| +1,088% | +$99.2K | ﹤0.01% | 5908 |
|
|
2025
Q1 | $13.1K | Buy |
5,270
+5,269
| +526,900% | +$13.1K | ﹤0.01% | 7162 |
|
|
2024
Q4 | $4 | Sell |
1
-1,084
| -100% | -$4.34K | ﹤0.01% | 8596 |
|
|
2024
Q3 | $6.34K | Sell |
1,085
-487
| -31% | -$2.84K | ﹤0.01% | 6769 |
|
|
2024
Q2 | $13.7K | Buy |
1,572
+1,571
| +157,100% | +$13.7K | ﹤0.01% | 6386 |
|
|
2024
Q1 | $13 | Sell |
1
-800
| -100% | -$10.4K | ﹤0.01% | 7896 |
|
|
2023
Q4 | $25.4K | Buy |
801
+652
| +438% | +$20.7K | ﹤0.01% | 5743 |
|
|
2023
Q3 | $3.67K | Buy |
+149
| New | +$3.67K | ﹤0.01% | 6383 |
|
|
2023
Q2 | – | Sell |
-90
| Closed | -$5.1K | – | 8389 |
|
|
2023
Q1 | $5.1K | Buy |
90
+37
| +70% | +$2.1K | ﹤0.01% | 6989 |
|
|
2022
Q4 | $5.73K | Buy |
53
+14
| +36% | +$1.51K | ﹤0.01% | 7940 |
|
|
2022
Q3 | $6K | Buy |
+39
| New | +$6K | ﹤0.01% | 7960 |
|
|
2022
Q2 | – | Sell |
-13
| Closed | -$15K | – | 9724 |
|
|
2022
Q1 | $15K | Buy |
13
+8
| +160% | +$9.23K | ﹤0.01% | 6801 |
|
|
2021
Q4 | $12K | Buy |
+5
| New | +$12K | ﹤0.01% | 7455 |
|
|
2021
Q2 | – | Sell |
-2
| Closed | -$16K | – | 8581 |
|
|
2021
Q1 | $16K | Sell |
2
-1
| -33% | -$8K | ﹤0.01% | 6558 |
|
|
2020
Q4 | $18K | Sell |
3
-6
| -67% | -$36K | ﹤0.01% | 6004 |
|
|
2020
Q3 | $33K | Buy |
9
+1
| +13% | +$3.67K | ﹤0.01% | 5078 |
|
|
2020
Q2 | $66K | Buy |
8
+7
| +700% | +$57.8K | ﹤0.01% | 4812 |
|
|
2020
Q1 | $11K | Buy |
+1
| New | +$11K | ﹤0.01% | 5969 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7179 |
|
|
2019
Q3 | – | Hold |
0
| – | -$7K | – | 7153 |
|
|
2019
Q2 | – | Hold |
0
| – | -$15K | – | 6373 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 5715 |
|